AVTX — Avalo Therapeutics Share Price
0.000.00%
Last trade - 00:00- $47.06m
- -$87.48m
- $0.44m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.35 | ||
| Price to Tang. Book | 0.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 106.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.65% | ||
| Return on Equity | -50.06% | ||
| Operating Margin | -15535.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.7 | 5.4 | 18.05 | 1.92 | 0.44 | n/a | n/a | -42.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Directors
- Michael Cola CHM (61)
- Schond Greenway CFO (49)
- Christopher Sullivan CAO (37)
- Garry Neil CSO (68)
- Stephen Smolinski OTH (56)
- Keith Maher DRC
- Joseph Miller DRC (47)
- June Almenoff IND (65)
- Steven Boyd IND (40)
- Mitchell Chan IND (40)
- Gilla Kaplan IND (74)
- Magnus Persson IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 31st, 2011
- Public Since
- November 13th, 2015
- No. of Shareholders
- 149
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,671,934
- Address
- 540 Gaither Road, Suite 400, ROCKVILLE, 20850
- Web
- https://www.avalotx.com/
- Phone
- +1 4105228707
- Auditors
- Ernst & Young LLP
Upcoming Events for AVTX
Q2 2025 Avalo Therapeutics Inc Earnings Release
Avalo Therapeutics Inc Annual Shareholders Meeting
Similar to AVTX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Avalo Therapeutics share price?
As of Today at 19:27 UTC, shares in Avalo Therapeutics are trading at $4.41. This share price information is delayed by 15 minutes.
How has the Avalo Therapeutics share price performed this year?
Shares in Avalo Therapeutics last closed at $4.41 and the price had moved by -67.62% over the past 365 days. In terms of relative price strength the Avalo Therapeutics share price has underperformed the S&P500 Index by -69.55% over the past year.
What are the analyst and broker recommendations for Avalo Therapeutics?
The overall consensus recommendation for Avalo Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Avalo Therapeutics dividend yield?
Avalo Therapeutics does not currently pay a dividend.
Does Avalo Therapeutics pay a dividend?
Avalo Therapeutics does not currently pay a dividend.
When does Avalo Therapeutics next pay dividends?
Avalo Therapeutics does not currently pay a dividend.
How do I buy Avalo Therapeutics shares?
To buy shares in Avalo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avalo Therapeutics?
As of the previous close price of $4.41, shares in Avalo Therapeutics had a market capitalisation of $47.06m.
Where are Avalo Therapeutics shares listed?
Here are the trading details for Avalo Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AVTX
What kind of share is Avalo Therapeutics?
Based on an overall assessment of its quality, value and momentum Avalo Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avalo Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Avalo Therapeutics is $31.50. That is 614.29% above the last closing price of $4.41.
Analysts covering Avalo Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.65 for the next financial year.
Find out moreWhat is the trend in the Avalo Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avalo Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -56.29%.
As of the last closing price of $4.41, shares in Avalo Therapeutics were trading -52.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avalo Therapeutics PE Ratio?
The Avalo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avalo Therapeutics?
Avalo Therapeutics' management team is headed by:
- Michael Cola - CHM
- Schond Greenway - CFO
- Christopher Sullivan - CAO
- Garry Neil - CSO
- Stephen Smolinski - OTH
- Keith Maher - DRC
- Joseph Miller - DRC
- June Almenoff - IND
- Steven Boyd - IND
- Mitchell Chan - IND
- Gilla Kaplan - IND
- Magnus Persson - IND